Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma
Introduction by the Guest Editor: Recent advances in biology and treatment of multiple myeloma
复制标题
客座编辑介绍：多发性骨髓瘤生物学和治疗的最新进展
DOI：
10.1007/s12185-020-02830-z
复制
发表时间：
2020
影响因子：
2.1
通讯作者：
Tanaka Hirokazu
中科院分区：
文献类型：
--
作者：
Takashi Kanamori;Shinsuke Iida;Tanaka Hirokazu
1 3如基于抗体的治疗、检查点抑制剂和嵌合抗原受体(CAR)工程的T细胞治疗已被开发为一种靶向免疫逃避骨髓瘤细胞的手段[7]。尽管在B细胞成熟抗原(BCMA)导向的CAR T细胞治疗方面取得了成功，但与CAR T细胞治疗相关的重大挑战仍然存在，目前正在进行必要的研究工作，以开发新的靶点和方法。Naoki Hosen博士总结了CAR T细胞疗法治疗多发性骨髓瘤领域的现状，并介绍了他们为开发一种新的CAR T细胞疗法所做的努力，该疗法更侧重于针对骨髓瘤细胞中优先检测到的蛋白质构象。我相信本期《血液学内科杂志》理解了多发性骨髓瘤重大进展的实质，并为它们目前的实际应用和未来的策略提供了数据，为MM患者提供了治愈的可能性。
1 3 such as antibody-based therapies, checkpoint inhibitors, and chimeric antigen receptor (CAR)-engineered T-cell therapies have been developed as a means of targeting immune evasion of myeloma cells [7]. Despite the successes on the development of B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, there remain significant challenges associated with CAR T-cell therapy and essential research efforts are currently in progress to develop new targets and approaches. Dr. Naoki Hosen summarizes the state of art in the field of CAR T-cell therapy against MM, and present their effort to develop a new CAR T-cell therapy with greater focus on targeting a protein conformation that is preferentially detected in myeloma cells. I am confident that this issue of Internal Journal of Hematology comprehends the essence of significant advances in MM and presents the data for their current practical utilization and future strategies that offer the possibility of a cure for patients with MM.